Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. Radiat Oncol 2019 Jun 26;14(1):114
Date
06/28/2019Pubmed ID
31242912Pubmed Central ID
PMC6595558DOI
10.1186/s13014-019-1277-1Scopus ID
2-s2.0-85068910566 (requires institutional sign-in at Scopus site) 32 CitationsAbstract
Clinical outcomes for patients with pancreatic adenocarcinoma (PAC) remain dismal. Local recurrences, proportions of margin positive surgical resections, and overall survival outcomes remain inferior in PAC than any other solid tumor. This stems from a current standard of care management approach that needs to be inspired and transformed with modern treatment techniques and novel therapeutic options. Radiation therapy has historically been a central component in the treatment of pancreatic adenocarcinoma; however, the role of radiation therapy has been called into question based on the publication of clinical trials with conflicting results. We present an overview of the rationale for radiation therapy in resectable, borderline resectable, and unresectable pancreatic adenocarcinoma. We further present a summary of emerging clinical data and future directions to improve outcomes in this devastating malignancy.
Author List
Hall WA, Goodman KAAuthor
William Adrian Hall MD Chair, Professor in the Radiation Oncology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdenocarcinomaDisease Management
Humans
Pancreatic Neoplasms
Radiotherapy
